J&J to Invest Over $55 Billion in U.S. Operations

Johnson & Johnson announced manufacturing, research and development, and technology investments of over $55 billion in the U.S. over the next four years in its Innovative Medicine and MedTech businesses. This reflects a 25% investment increase compared to the company’s previous four year period.

J&J revealed this as it broke ground on a new 500,000-square-foot biologics manufacturing facility located in Wilson, N.C. The facility will focus on next-gen medicines for cancer, autoimmune disorders, and neurological diseases.

The company will also build three new advanced manufacturing facilities and expand existing sites for its Innovative Medicine and MedTech businesses. Further details have not yet been disclosed.

Further, J&J plans to invest in its R&D for cardiovascular disease, neuroscience, oncology, immunology, and robotic surgery. It pointed to the 2017 Tax Cuts and Jobs Act as the catalyst for building on its U.S. investment levels.

“Today’s announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world’s toughest healthcare challenges,” said Joaquin Duato, chairman and CEO of Johnson & Johnson. “Our increased U.S. investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add U.S.-based jobs but manufacture cutting edge medicines to treat patients in America and around the world.”